Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213463 | 1.00 | PARP1 (0.35) | PARP1HRH3ATRSCN3A | |
| SCHEMBL14213470 | 1.00 | PARP1 (0.35) | PARP1HRH3ATRSCN3A | |
| SCHEMBL14213467 | 0.81 | PARP1 (0.40) | PARP1 | |
| SCHEMBL14213459 | 0.81 | PARP1 (0.40) | PARP1 | |
| SCHEMBL8215178 | 0.81 | PARP1 (0.40) | PARP1 | |
| SCHEMBL4104943 | 0.78 | NTRK1 (0.46) | — | |
| SCHEMBL4095007 | 0.77 | NTRK1 (0.42) | PARP1ATR | |
| SCHEMBL18791259 | 0.77 | NTRK1 (0.38) | PARP1 | |
| SCHEMBL19560132 | 0.75 | NTRK1 (0.46) | — | |
| SCHEMBL4102101 | 0.75 | NTRK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | PARP1 1305/4885HRH3 1736/4885ATR 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.